T lymphocytes as therapeutic arsenal for patients with hematological malignancies

Montoro, Juan; Piñana, José Luís; Sanz, Jaime; Guerreiro, Manuel

doi:10.1097/cco.0000000000000481

Cited by 4 publications

(3 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cellular immunity is comprised of two types: specific binding and destructing the plasma membrane of target cells via forming a transmembrane pore, and direct killing of target cells. 39 Most of the activated CD4(+) T cells can stimulate the aggregation of cytokines, and secrete the IL-12, IFN-γ (interferon-γ) and other pro-inflammatory cytokines that ultimately resulting in inflammation. 40 According to the reported studies, 41 tan-IIA elevates the level of anti-inflammatory cytokines, such as IL-10, while decreases the level of inflammatory cytokines, such as IL-2, IL-4.…”

Section: Tanshinone Iia Has a Significant Contribution To The Developmentioning

confidence: 99%

<p>Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases</p>

Guo

et al. 2020

DDDT

191

View full text Add to dashboard Cite

Salvia miltiorrhiza : (Danshen) is a significant (traditional Chinese medication) natural remedy, enhancing blood circulation and clear blood stasis. In this view, it is widely used against several heart diseases, eg, cardiomyopathy, arrhythmia, and congenital heart defects. Tanshinone IIA (tan-IIA) is the main fat-soluble component of Salvia miltiorrhiza . Modern pharmacological study shows that tan-IIA has anti-inflammatory and anti-oxidant activities. Tan-IIA induces remarkable cardioprotective effects via enhancing angiogenesis which may serve as an effective treatment against cardiovascular diseases (CVD). There is also evidence that tan-IIA has extensive immunomodulatory effects and plays a significant role in the development and function of immune cells. Tan-IIA reduces the production of inflammatory mediators and restores abnormal signaling pathways via regulating the function and activation of immune cells. It can also regulate signal transduction pathways, ie, TLR/NF-κB pathway and MAPKs/NF-κB pathway, thereby tan-IIA has an anti-inflammatory, anticoagulant, antithrombotic and neuroprotective role. It plays a protective role in the pathogenesis of cardiovascular disorders (ie, atherosclerosis, hypertension) and Alzheimer’s disease. It has also been revealed that tan-IIA has an anti-tumor role by killing various tumor cells, inducing differentiation and apoptosis, and has potential activity against carcinoma progression. In the review of this fact, the tan-IIA role in different diseases and its mechanism have been summarized while its clinical applications are also explored to provide a new perspective of Salvia miltiorrhiza . An extensive study on the mechanism of action of tan-IIA is of great significance for the effective use of Chinese herbal medicine and the promotion of its status and influence on the world.

show abstract

Section: Tanshinone Iia Has a Significant Contribution To The Developmentioning

confidence: 99%

<p>Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases</p>

Guo

et al. 2020

DDDT

191

View full text Add to dashboard Cite

show abstract

“…(iv) Chimeric Antigen Receptor T‐cells (CART‐cells) are genetically engineered T cells designed specifically to destroy tumor cells. The current CART cells available in the clinic are of autologous origin, 19 but allogeneic cells can offer advantages, such as the availability of “fit” cells for production. However, allogeneic T cell therapies must address HLA barriers and rely on the availability of a suitable HLA‐matched donor 20 .…”

Section: Introductionmentioning

confidence: 99%

Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high‐resolution analysis

Guerreiro

Planelles

Aguilar-Gallardo

et al. 2021

HLA

Self Cite

View full text Add to dashboard Cite

There are many studies on the polymorphism of the HLA system in healthy donor populations, such as registries of unrelated bone marrow donors. Investigations on the characterization of the HLA complex in hematopoietic stem cell transplant (HSCT) patients, however, are scarce, at least in the Spanish population. This study presents a large‐scale analysis of allelic diversity and HLA distribution at a high‐resolution level in 2886 patients undergoing HSCT in Spanish centres of the “Grupo Español de Trasplante Hematopoyético y Terapia Celular” during a period of 11 years. Allelic diversity analysis identified 67 HLA‐A, 133 HLA‐B, 60 HLA‐C, 63 HLA‐DRB1, 24 HLA‐DQB1 and 27 HLA‐DPB1 different alleles. Rare alleles were detected among which 33 alleles had not been reported in the European catalog of common and well‐documented HLA alleles. Regarding the distribution of five genes‐haplotypes, it was observed that the five most frequent extended haplotypes found in our population were between the most common in other Spanish populations, both in patients and in healthy subjects. However, some particular haplotypes were also detected. Bilocus associations HLA‐C ~ B and ‐DRB1 ~ DQB1 were analyzed in order to predict the probability of finding 10/10 matched donors in registries. We found HLA‐B alleles showing a great diversity of combinations with HLA‐C alleles and unusual associations involving a negative predicting factor. In the field of adoptive therapies, our work supports the necessity to expand further research of TCR‐engineered cells, adoptive transfer of virus‐specific T‐cells and vaccines to target HLA alleles other than A*02:01. HLA alleles such as A*01:01, A*03:01, A*24:02, B*44:03, B*07:02 or B*51:01, might be considered new targets due to its high frequency in our population.

show abstract

“…Lymphocytes are the main immune cells of the body, with T lymphocytes and NK cells both playing an immune role in tumors. T lymphocytes in particular have an inhibitory effect on distant metastasis of tumors ( 29 , 30 ). As NLR is the ratio of neutrophils to lymphocytes, the increase of NLR in cancer patients suggests that the body’s anti-tumor function might decrease and tumor progression or metastasis is more likely to occur.…”

Section: Discussionmentioning

confidence: 99%

Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR- mutant Non-small cell lung cancer

Xu¹,

Yao²,

Li³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background Neutrophil-lymphocyte ratio (NLR) has been reported as a prognostic biomarker in various cancers, but its prognostic value for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs) remains unclear. To address this issue, we performed a retrospective study to investigate the clinical value of NLR in these patients. Methods All data were collected from medical records. Sixty-five cases with stage IIIB-IVB EGFR-mutant NSCLC treated with EGFR-TKIs were enrolled. The pretreatment NLR was analyzed for associations with disease control rate (DCR) and progression-free survival (PFS). The primary outcomes of interest were DCR and PFS. All the data were analyzed using SPSS 23.0. The PFS curves were plotted by Kaplan-Meier analysis and log-rank test. Univariate and multivariate Cox regression analyses were used to determine the factors affecting PFS. Results The results indicated that, compared with those with lower NLR (<2.57), the patients with a higher NLR (≥2.57) showed a significantly shorter PFS (8.8 vs . 12.2 months, P<0.01), and decreased DCR by the end of 8, 10 months after TKIs treatment (62.5% vs . 93.3%, P=0.014; 38.5% vs . 77.8%, P=0.037). COX multivariate analysis showed that NLR was an independent prognostic factor for PFS (P<0.001). Conclusions Elevated NLR is significantly associated with lower DCR, shorter PFS, and might act as a meaningful biomarker for predicting the efficacy of TKIs treatment and the prognosis of advanced EGFR-mutant NSCLC. High-quality prospective clinical trials with longer follow-up are needed to further confirm the results.

show abstract

T lymphocytes as therapeutic arsenal for patients with hematological malignancies

Abstract: We highlight recent advances and discuss future directions of T-cell-based immunotherapies entering the common clinical practice in hematology.

Cited by 4 publications

References 126 publications

<p>Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases</p>

<p>Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases</p>

Allogeneic hematopoietic stem cell transplant recipients in Spain: Human leukocyte antigen characteristics and diversity by high‐resolution analysis

Pretreatment neutrophil-to-lymphocyte ratio is a predictive biomarker for EGFR TKI-treated patients with advanced EGFR- mutant Non-small cell lung cancer

Contact Info

Product

Resources

About